Between 2005 to 2015, the pharma sector was one of the best performing sectors with stocks creating big wealth for the shareholders. Then came a spate of US FDA inspections and observation and a number of companies witnessed a sharp decline in performance. Over the next few years, stocks underperformed as companies went into introspection and course correction. Some of them have been able to make a comeback both in terms of operations and product portfolio. While there are some risks present in the system but given the fact they have come into under owned category, any positive news may have higher positive impact.